crc press - E-Lib FK UWKS

394 Cell-Penetrating Peptides: Processes and Applications
27. Fernandez-Lopez, S. et al., Antibacterial agents based on the cyclic D,L-alpha-peptide
architecture, Nature, 412, 452, 2001.
28. Shai, Y., Mechanism of the binding, insertion and destabilization of phospholipid
bilayer membranes by alpha-helical antimicrobial and cell non-selective membranelytic
peptides, Biochim. Biophys. Acta, 1462, 55, 1999.
29. Huang, H.W., Action of antimicrobial peptides: two-state model, Biochemistry, 39,
8347, 2000.
30. Matsuzaki, K., Why and how are peptide-lipid interactions utilized for self-defense?
Magainins and tachyplesins as archetypes, Biochim. Biophys. Acta, 1462, 1, 1999.
31. Kobayashi, S. et al., Interactions of the novel antimicrobial peptide buforin 2 with
lipid bilayers: proline as a translocation promoting factor, Biochemistry, 39, 8648,
2000.
32. Zhang, L., Rozek, A., and Hancock, R.E., Interaction of cationic antimicrobial peptides
with model membranes, J. Biol. Chem., 25, 25, 2001.
33. Guo, L. et al., Lipid A acylation and bacterial resistance against vertebrate antimicrobial
peptides, Cell, 95, 189, 1998.
34. Friedrich, C. et al., Salt-resistant alpha-helical cationic antimicrobial peptides, Antimicrob.
Agents Chemother., 43, 1542, 1999.
35. Tossi, A., Sandri, L., and Giangaspero, A., Amphipathic, alpha-helical antimicrobial
peptides, Biopolymers, 55, 4, 2000.
36. Naider, F. and Becker, J. M., Peptide transport in Candida albicans: implications for
the development of antifungal agents, Curr. Top. Med. Mycol., 2, 170, 1988.
37. Hancock, R.E.W., Drug Transport in Antimicrobial and Anticancer Chemotherapy,
Marcel Dekker, New York, 1994.
38. Sandvig, K. and van Deurs, B., Endocytosis and intracellular transport of ricin: recent
discoveries, FEBS Lett., 452, 67, 1999.
39. Falnes, P.O. and Sandvig, K., Penetration of protein toxins into cells, Curr. Opin.
Cell Biol., 12, 407, 2000.
40. Sandvig, K. and van Deurs, B., Entry of ricin and Shiga toxin into cells: molecular
mechanisms and medical perspectives, Embo J., 19, 5943, 2000.
41. Westerhoff, H.V. et al., Magainins and the disruption of membrane-linked free-energy
transduction, Proc. Natl. Acad. Sci. U.S.A., 86, 6597, 1989.
42. Yang, L. et al., Crystallization of antimicrobial pores in membranes: magainin and
protegrin, Biophys. J., 79, 2002, 2000.
43. Kragol, G. et al., The antibacterial peptide pyrrhocoricin inhibits the ATPase actions
of DnaK and prevents chaperone-assisted protein folding, Biochemistry, 40, 3016,
2001.
44. Sharma, S. and Khuller, G., DNA as the intracellular secondary target for antibacterial
action of human neutrophil peptide-I against Mycobacterium tuberculosis H37Ra,
Curr. Microbiol., 43, 74, 2001.
45. Helmerhorst, E.J. et al., The cellular target of histatin 5 on Candida albicans is the
energized mitochondrion, J. Biol. Chem., 274, 7286, 1999.
46. Debono, M. and Gordee, R.S., Antibiotics that inhibit fungal cell wall development,
Annu. Rev. Microbiol., 48, 471, 1994.
47. Lupetti, A. et al., Candidacidal activities of human lactoferrin peptides derived from
the N terminus, Antimicrob. Agents Chemother., 44, 3257, 2000.
48. Boman, H.G. et al., Antibacterial and antimalarial properties of peptides that are
cecropin-melittin hybrids, FEBS Lett., 259, 103, 1989.
49. Andreu, D. et al., Shortened cecropin A-melittin hybrids. Significant size reduction
retains potent antibiotic activity, FEBS Lett., 296, 190, 1992.